The Hepatitis B Core Antibody Testing Group published an interim report in March 1984 and a full report in July 1984, and deemed that testing was not necessary. Read more about The Hepatitis B Core Antibody Testing Group published an interim report in March 1984 and a full report in July 1984, and deemed that testing was not necessary.
Dr Ojala of Cutter sent a memo to Whilhelm Schaeffler noting that the time had come for hepatitis core anti-body testing for plasma. Read more about Dr Ojala of Cutter sent a memo to Whilhelm Schaeffler noting that the time had come for hepatitis core anti-body testing for plasma.
Recommendations by the National Hemophilia Foundation's Medical and Scientific Advisory Committee were for the "Evaluation and implementation (if verified) of surrogate laboratory tests that would identify individuals at high risk of AIDS transmission." Read more about Recommendations by the National Hemophilia Foundation's Medical and Scientific Advisory Committee were for the "Evaluation and implementation (if verified) of surrogate laboratory tests that would identify individuals at high risk of AIDS transmission."
Anti-HBc testing came to be regarded, and argued over, as the most likely surrogate test as the epidemiological pattern of AIDS was considered to be similar to that of Hepatitis B. Read more about Anti-HBc testing came to be regarded, and argued over, as the most likely surrogate test as the epidemiological pattern of AIDS was considered to be similar to that of Hepatitis B.
The American Blood Association made a public statement accepting that the cases of AIDS in people with haemophilia "suggest that AIDS may be of infectious etiology" and the organisation urged that "steps be taken as soon as possible to screen plasma donors to minimize the possibility of transmitting AIDS." Read more about The American Blood Association made a public statement accepting that the cases of AIDS in people with haemophilia "suggest that AIDS may be of infectious etiology" and the organisation urged that "steps be taken as soon as possible to screen plasma donors to minimize the possibility of transmitting AIDS."
Alpha's insistence on the measures taken pertaining to high-risk donors meant that they lost contracts with some blood banks that sold recovered plasma as they were not prepared to implement them. Read more about Alpha's insistence on the measures taken pertaining to high-risk donors meant that they lost contracts with some blood banks that sold recovered plasma as they were not prepared to implement them.
By the summer of 1983, 800 potential donors had "voluntarily disqualified themselves from the pool." Read more about By the summer of 1983, 800 potential donors had "voluntarily disqualified themselves from the pool."
Dr Clyde McAuley, Alpha's medical director, was quoted as saying "So long as there is any question about the involvement of blood products, Alpha is taking all possible steps to reduce the potential risk for the hemophiliac receiving our factor VIII and factor IX concentrates." Read more about Dr Clyde McAuley, Alpha's medical director, was quoted as saying "So long as there is any question about the involvement of blood products, Alpha is taking all possible steps to reduce the potential risk for the hemophiliac receiving our factor VIII and factor IX concentrates."
Documents recorded that it was estimated that prison plasma accounted for approximately 2% of the total plasma collected in the US as of mid 1982 and was obtained from no more than six to eight centres. Read more about Documents recorded that it was estimated that prison plasma accounted for approximately 2% of the total plasma collected in the US as of mid 1982 and was obtained from no more than six to eight centres.
The US Public Health Service announced recommendations for the prevention of AIDS in patients with haemophilia and for other recipients of blood and blood products so that a uniform set of recommendations might be developed. Read more about The US Public Health Service announced recommendations for the prevention of AIDS in patients with haemophilia and for other recipients of blood and blood products so that a uniform set of recommendations might be developed.